Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial

Malaria caused by Plasmodium falciparum continues to be a major cause of disease and death in sub-Saharan Africa. 306 men aged 18-45 years were randomly assigned 3 doses of either RTS,S/AS02 or rabies vaccine (control). Volunteers were given sulfadoxine /pyrimethamine 2 weeks before dose 3, and kept...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2001-12, Vol.8, p.1927-1934
Main Authors: Bojang, K A, Milligan, P J M, Pinder, M, Vigneron, L, Alloueche, A, Kester, K E, Ballou, W R, Conway, D J, Reece, W H H, Gothard, P, Yamuah, L, Delchambre, M, Voss, G, Greenwood, B M, Hill, A, McAdam, K P W J, Tornieporth, N, Cohen, J D, Doherty, T
Format: Article
Language:English
Subjects:
Efficacy
Gambia
Immunological status
Malaria
Men
Randomized controlled trials
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malaria caused by Plasmodium falciparum continues to be a major cause of disease and death in sub-Saharan Africa. 306 men aged 18-45 years were randomly assigned 3 doses of either RTS,S/AS02 or rabies vaccine (control). Volunteers were given sulfadoxine /pyrimethamine 2 weeks before dose 3, and kept under surveillance throughout the malaria transmission season. Blood smears were collected once a week and whenever a volunteer developed symptoms compatible with malaria. Found that RTS,S/AS02 is safe, immunogenic, and is the first pre-erythrocytic vaccine to show significant protection against natural Plasmodium falciparum infection. (Original abstract - amended)
ISSN:0140-6736